Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 1, 2000, Pages 45-48

  Dragovich, Peter S ^a   Zhou, Ru ^a   Webber, Stephen E ^a   Prins, Thomas J ^a   Kwok, Annette K ^a   Okano, Koji ^a,b   Fuhrman, Shella A ^a   Zalman, Leora S ^a   Maldonado, Fausto C ^a   Brown, Edward L ^a   Meador, James W ^a   Patick, Amy K ^a   Ford, Clifford E ^a   Brothers, Mary A ^a   Binford, Susan L ^a   Matthews, David A ^a   Ferre, Rose Ann ^a   Worland, Stephen T ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

^b JAPAN TOBACCO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; KETONE; PROTEINASE INHIBITOR; TRIPEPTIDE; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RHINOVIRUS; VIRUS INHIBITION;

ANTIVIRAL AGENTS; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; KETONES; KINETICS; OLIGOPEPTIDES; RHINOVIRUS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS;

HUMAN RHINOVIRUS 3; HUMAN RHINOVIRUS SP.; RHINOVIRUS;

EID: 10744224941     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00587-9     Document Type: Article

References (30)

1. Couch, R. B. In Fields Virology, 3rd Ed.; Fields, B. N.; Knipe, D. M.; Howley, P. M. Eds.; Lippincott-Raven: Philadelphia, 1996; Vol. 1, Chapter 23, pp. 713-734 and references therein.
2. Rueckert, R. R. In Fields Virology, 3rd Ed.; Fields, B. N.; Knipe, D. M.; Howley, P. M. Eds.; Lippincott-Raven: Philadelphia, 1996; Vol. 1, Chapter 21, pp. 609-654 and references therein.
3. Orr D.C., Long A.C., Kay J., Dunn B.M., Cameron J.M. J. Gen. Virol. 70:1989;2931.
4. Cordingley M.G., Callahan P.L., Sardana V.V., Garsky V.M., Colonno R.J. J. Biol. Chem. 265:1990;9062.
5. Matthews D.A., Smith W.W., Ferre R.A., Condon B., Budahazi G., Sisson W., Villafranca J.E., Janson C.A., McElroy H.E., Gribskov C.L., Worland S. Cell. 77:1994;761.
6. Dragovich, P. S; Webber, S. E.; Prins, T. J.; Zhou, R.; Marakovits, J. T.; Tikhe, J. G.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Ford, C. E.; Brown, E. L.; Binford, S. L.; Meador, J. W., III; Ferre, R. A.; Worland, S. T. Bioorg. Med. Chem. Lett. 1999, 9, 2189 and references therein.
7. 2′, etc.) is described in: Schechter, I.; Berger, A. Biochem. Biophys. Res. Commun. 1967, 27, 157.
8. Webber S.E., Okano K., Little T.L., Reich S.H., Xin Y., Fuhrman S.A., Matthews D.A., Hendrickson T.F., Love R.A., Patick A.K., Meador J.W. III, Ferre R.A., Brown E.L., Ford C.E., Binford S.L., Worland S.T. J. Med. Chem. 41:1998;2786.
9. Shepherd T.A., Cox G.A., McKinney E., Tang J., Wakulchik M., Zimmerman R.E., Villarreal E.C. Bioorg. Med. Chem. Lett. 6:1996;2893.
10. Kaldor S.W., Hammond M., Dressman B.A., Labus J.M., Chadwell F.W., Kline A.D., Heinz B.A. Bioorg. Med. Chem. Lett. 5:1995;2021.
11. Malcolm B.A., Lowe C., Shechosky S., McKay R.T., Yang C.C., Shah V.J., Simon R.J., Vederas J.C., Santi D.V. Biochemistry. 34:1995;8172.
12. 1 glutamine isostere to avoid possible intramolecular hemiaminal formation. See refs 8-11 for additional details.
13. Edwards P.D., Bernstein P.R. Med. Res. Rev. 14:1994;127.
14. Marquis R.W., Yamashita D.S., Ru Y., LoCastro S.M., Oh H.-J., Erhard K.F., Desjarlais R.L., Head M.S., Smith W.W., Zhao B., Janson C.A., Abdel-Maguid S.S., Tomaszek T.A., Levy M.A., Veber D.F. J. Med. Chem. 41:1998;3563.
15. Tao M., Bihovsky R., Kauer J.C. Bioorg. Med. Chem. Lett. 6:1996;3009.
16. Mjalli A.M.M., Chapman K.T., MacCoss M., Thornberry N.A., Peterson E.P. Bioorg. Med. Chem. Lett. 4:1994;1965.
17. Akiyama Y., Tsutsumi S., Hatsushiba E., Ohuchi S., Okonogi T. Bioorg. Med. Chem. Lett. 7:1997;533.
18. Costanzo M.J., Maryanoff B.E., Hecker L.R., Schott M.R., Yabut S.C., Zhang H.-C., Andrade-Gordon P., Kauffman J.A., Lewis J.M., Krishnan R., Tulinsky A. J. Med. Chem. 39:1996;3039.
19. Edwards P.D., Zottola M.A., Davis M., Williams J., Tuthill P.A. J. Med. Chem. 38:1995;3972.
20. Edwards P.D., Wolanin D.J., Andisik D.W., Davis M.W. J. Med. Chem. 38:1995;76.
21. Tsutsumi S., Okonogi T., Shibahara S., Ohuchi S., Hatsushiba E., Patchett A.A., Christensen B.G. J. Med. Chem. 37:1994;3492.
22. Edwards P.D., Meyer E.F. Jr., Vijayalakshmi J., Tuthill P.A., Andisik D.A., Gomes B., Strimpler A. J. Am. Chem. Soc. 114:1992;1854.
23. Dragovich P.S., Prins T.J., Zhou R., Webber S.E., Marakovits J.T., Fuhrman S.A., Patick A.K., Matthews D.A., Lee C.A., Ford C.E., Burke B.J., Rejto P.A., Hendrickson T.F., Tuntland T., Brown E.L., Meador J.W. III, Ferre R.A., Harr J.E.V., Kosa M.B., Worland S.T. J. Med. Chem. 42:1999;1213.
24. 1-lactam moiety contained in 5 may also attenuate intramolecular hemiaminoketal formation relative to 3. The extent to which such hemiaminoketal formation (if any) affects 3CP inhibition is currently not known.
25. Enzyme and antiviral assays were performed as described in Webber, S. E.; Tikhe J.; Worland, S. T.; Fuhrman, S. A.; Hendrickson, T. F.; Matthews, D. A.; Love, R. A.; Patick, A. K.; Meador, J. W.; Ferre, R. A.; Brown, E. L.; DeLisle, D. M.; Ford, C. E.; Binford, S. L. J. Med. Chem. 1996, 39, 5072.
26. Matthews, D. A., unpublished results.
27. Intermediate 12 was prepared as described in ref 8. Intermediate 15 was prepared as described in Dragovich, P. S.; Webber, S. E.; Babine, R. E.; Fuhrman, S. E.; Patick, A. K.; Matthews, D. A.; Lee, C. A.; Reich, S. H.; Prins, T. J.; Marakovits, J. T.; Littlefield, E. S.; Zhou, R.; Tikhe, J.; Ford, C. E.; Wallace, M. B.; Meador, J. W., III; Ferre, R. A.; Brown, E. L.; Binford, S. L.; Harr, J. E. V.; DeLisle, D. M.; Worland, S. T. J. Med. Chem. 1998, 41, 2806. Intermediate 18 was prepared as described in ref 23.
28. Nahm S., Weinreb S.M. Tetrahedron Lett. 22:1981;3815.
29. 1H NMR during the preparation of other tripeptidyl ketones.
30. In several instances, the DMB group was removed from intermediate 21 prior to conversion to final compounds 5-10. Either synthetic sequence afforded the desired products in acceptable overall yields.